Karuna Therapeutics, Inc. (KRTX)

NASDAQ: KRTX · IEX Real-Time Price · USD
182.42
+6.20 (3.52%)
At close: Mar 24, 2023, 4:00 PM
182.02
-0.40 (-0.22%)
After-hours: Mar 24, 2023, 7:39 PM EDT
3.52%
Market Cap 6.37B
Revenue (ttm) 10.64M
Net Income (ttm) -276.34M
Shares Out 34.89M
EPS (ttm) -8.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 922,451
Open 176.03
Previous Close 176.22
Day's Range 174.40 - 183.34
52-Week Range 92.26 - 278.25
Beta 1.17
Analysts Buy
Price Target 288.00 (+57.88%)
Earnings Date May 4, 2023

About KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psych... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2019
Employees 118
Stock Exchange NASDAQ
Ticker Symbol KRTX
Full Company Profile

Financial Performance

In 2022, KRTX's revenue was $10.64 million, a decrease of -71.22% compared to the previous year's $36.96 million. Losses were -$276.34 million, 92.2% more than in 2021.

Financial Statements

Analyst Forecast

According to 27 analysts, the average rating for KRTX stock is "Buy." The 12-month stock price forecast is $288.0, which is an increase of 57.88% from the latest price.

Price Target
$288.0
(57.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc.

5 hours ago - Business Wire

Karuna Therapeutics to Present at the Stifel 2023 CNS Days

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a...

1 day ago - Business Wire

Karuna Therapeutics Announces Pricing of Public Offering of Common Stock

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

3 days ago - Business Wire

Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study

Data from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to an early and sustained statistically significant reduction of symptoms of schizophrenia.

3 days ago - Zacks Investment Research

Karuna Therapeutics Announces Proposed Public Offering of Common Stock

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

4 days ago - Business Wire

Why Is Karuna Therapeutics (KRTX) Stock Moving Today?

Karuna Therapeutics (NASDAQ: KRTX) stock is on the move Monday after releasing results from a Phase 3 clinical trial for KarXT. KarXT is a drug in development by the company to treat adults with schi...

4 days ago - InvestorPlace

Karuna's stock is up after schizophrenia drugs meets primary endpoint in clinical trial

Shares of Karuna Therapeutics Inc. KRTX, +1.21% rallied about 14% in premarket trading on Monday after the company said its experimental treatment for adults with schizophrenia met the primary endpoin...

4 days ago - Market Watch

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

4 days ago - Business Wire

Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q4

Karuna Therapeutics (KRTX) reports encouraging fourth-quarter 2022 results. The company beats estimates for earnings and sales.

1 month ago - Zacks Investment Research

Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

1 month ago - Business Wire

Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

1 month ago - Business Wire

Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates

Karuna Therapeutics (KRTX) announces a definitive agreement with Goldfinch Bio to acquire global rights to the latter's lead clinical-stage candidate, GFB-887 and TRPC4/5 channel candidates.

1 month ago - Zacks Investment Research

Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio's Investigational TRPC4/5 Product Candidates

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX) and GFB (ABC), LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement...

1 month ago - Business Wire

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric...

1 month ago - Business Wire

Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric...

2 months ago - Business Wire

Moore Kuehn, PLLC Encourages Investors of Karuna Therapeutics, Inc. to Contact Law Firm

NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Karuna Therapeutics, Inc. (NASDAQ: ...

3 months ago - PRNewsWire

7 Best Small-Cap Stocks to Buy for 2022 and Beyond

Analysts say a tough 2022 has left these small-cap stocks priced for outperformance in the new year and beyond.

3 months ago - Kiplinger

Why Karuna Therapeutics Shares Are Trading Sharply Lower - Karuna Therapeutics (NASDAQ:KRTX)

Karuna Therapeutics Inc KRTX shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition.

3 months ago - Benzinga

Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric...

3 months ago - Business Wire

Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss

Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.

5 months ago - Zacks Investment Research

Karuna Therapeutics, Inc. (KRTX) Reports Q3 Loss, Misses Revenue Estimates

Karuna Therapeutics, Inc. (KRTX) delivered earnings and revenue surprises of -19.60% and 99.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

5 months ago - Zacks Investment Research

Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

5 months ago - Business Wire

Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

5 months ago - Business Wire

PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics

PARAMUS, N.J.--(BUSINESS WIRE)--PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage ...

5 months ago - Business Wire

Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy...

6 months ago - Business Wire